| |
Correct -- old news -- as a matter of fact, this angiogenesis stuff is all old news. Taxol derived from the yew tree from which paclitaxel is derived is an angiogenesis type drug in that it starves the tumor cells of blood supply -- and seems to work on a wide variety of tumors from breast, renal, Kaposi's Sarcoma, etc. I don't know if Entremed's drug has a taxol element but I do know that Imclone's C225 has a taxol base. It is my guess that all of these angiogenesis drugs have some sort of taxol base and are differentiated through a biochemical process that improves efficacy. If Entremed does have a cure all tumor killing drug, I would be surprised because cancer tumors vary considerably in shape, size, and structure. If they do, obviously it's a money machine. I'm no expert by any stretch of the imagination, but I still doubt it.
Interesting that a broker raised his target for IMCL from $13.00 to $16.00. I'd like to know his reasoning since there really hasn't been much in the way of news lately.
Jackson |
|
